635 related articles for article (PubMed ID: 30294326)
1. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
van de Donk NWCJ; Usmani SZ
Front Immunol; 2018; 9():2134. PubMed ID: 30294326
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
Martin TG; Corzo K; Chiron M; Velde HV; Abbadessa G; Campana F; Solanki M; Meng R; Lee H; Wiederschain D; Zhu C; Rak A; Anderson KC
Cells; 2019 Nov; 8(12):. PubMed ID: 31779273
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.
Saltarella I; Desantis V; Melaccio A; Solimando AG; Lamanuzzi A; Ria R; Storlazzi CT; Mariggiò MA; Vacca A; Frassanito MA
Cells; 2020 Jan; 9(1):. PubMed ID: 31936617
[TBL] [Abstract][Full Text] [Related]
5. CD38 antibodies in multiple myeloma: back to the future.
van de Donk NWCJ; Richardson PG; Malavasi F
Blood; 2018 Jan; 131(1):13-29. PubMed ID: 29118010
[TBL] [Abstract][Full Text] [Related]
6. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
Zhu C; Song Z; Wang A; Srinivasan S; Yang G; Greco R; Theilhaber J; Shehu E; Wu L; Yang ZY; Passe-Coutrin W; Fournier A; Tai YT; Anderson KC; Wiederschain D; Bahjat K; Adrián FJ; Chiron M
Front Immunol; 2020; 11():1771. PubMed ID: 32922390
[TBL] [Abstract][Full Text] [Related]
7. [CD38 antibodies in multiple myeloma].
Moreaux J
Med Sci (Paris); 2019 Dec; 35(12):1001-1004. PubMed ID: 31903907
[TBL] [Abstract][Full Text] [Related]
8. Anti CD38 monoclonal antibodies for multiple myeloma treatment.
Gozzetti A; Ciofini S; Simoncelli M; Santoni A; Pacelli P; Raspadori D; Bocchia M
Hum Vaccin Immunother; 2022 Nov; 18(5):2052658. PubMed ID: 35404740
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Krejcik J; Casneuf T; Nijhof IS; Verbist B; Bald J; Plesner T; Syed K; Liu K; van de Donk NW; Weiss BM; Ahmadi T; Lokhorst HM; Mutis T; Sasser AK
Blood; 2016 Jul; 128(3):384-94. PubMed ID: 27222480
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
van de Donk NW; Janmaat ML; Mutis T; Lammerts van Bueren JJ; Ahmadi T; Sasser AK; Lokhorst HM; Parren PW
Immunol Rev; 2016 Mar; 270(1):95-112. PubMed ID: 26864107
[TBL] [Abstract][Full Text] [Related]
11. Targeting NAD
Kennedy BE; Sadek M; Elnenaei MO; Reiman A; Gujar SA
Trends Cancer; 2020 Jan; 6(1):9-12. PubMed ID: 31952784
[TBL] [Abstract][Full Text] [Related]
12. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Kassem S; Diallo BK; El-Murr N; Carrié N; Tang A; Fournier A; Bonnevaux H; Nicolazzi C; Cuisinier M; Arnould I; Sidhu SS; Corre J; Avet-Loiseau H; Teillaud JL; van de Velde H; Wiederschain D; Chiron M; Martinet L; Virone-Oddos A
Blood; 2022 Feb; 139(8):1160-1176. PubMed ID: 35201323
[TBL] [Abstract][Full Text] [Related]
13. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
Plesner T; van de Donk N; Richardson PG
Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
[TBL] [Abstract][Full Text] [Related]
14. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
15. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
Manna A; Aulakh S; Jani P; Ahmed S; Akhtar S; Coignet M; Heckman M; Meghji Z; Bhatia K; Sharma A; Sher T; Alegria V; Malavasi F; Chini EN; Chanan-Khan A; Ailawadhi S; Paulus A
Clin Cancer Res; 2019 Jul; 25(13):3974-3985. PubMed ID: 30940652
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
17. Reprint of "Immunomodulatory effects of CD38-targeting antibodies".
van de Donk NWCJ
Immunol Lett; 2019 Jan; 205():71-77. PubMed ID: 30826127
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
Sanchez L; Wang Y; Siegel DS; Wang ML
J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
[TBL] [Abstract][Full Text] [Related]
19. CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.
Wang H; Koob T; Fromm JR; Gopal A; Carter D; Lieber A
Cancer Biol Ther; 2024 Dec; 25(1):2314322. PubMed ID: 38361357
[TBL] [Abstract][Full Text] [Related]
20. CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers.
Jiao Y; Yi M; Xu L; Chu Q; Yan Y; Luo S; Wu K
Expert Opin Investig Drugs; 2020 Nov; 29(11):1295-1308. PubMed ID: 32822558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
